Docetaxel for injection (Albumin-bound)
Phase 3Small molecule
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Docetaxel for injection (Albumin-bound) is one of 117 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.
4
Indications
8
Total Trials
4
Active Trials
116
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
306 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Docetaxel for injection (Albumin-bound)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Active Comparator
ModernaPreclinical
Secretin-Ferring
FerringPreclinical
Sulfonylureas
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Cancer2 trials
Gastric Cancer2 trials
Sources
References
- [1]
- [2]
- [3]
- [4]
Details